Literature DB >> 11409870

Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations.

E Serra1, E Ars, A Ravella, A Sánchez, S Puig, T Rosenbaum, X Estivill, C Lázaro.   

Abstract

Neurofibromas, benign tumors that originate from the peripheral nerve sheath, are a hallmark of neurofibromatosis type 1 (NF1). Although loss of heterozygosity (LOH) is a common phenomenon in this neoplasia, it only accounts for part of the somatic NF1 mutations found. Somatic point mutations or the presence of "two hits" in the NF1 gene have only been reported for a few neurofibromas. The large size of the NF1 gene together with the multicellular composition of these tumors has greatly hampered their molecular characterization. Here, we present the somatic NF1 mutational analysis of the whole set of neurofibromas studied by our group and consisting in 126 tumors derived from 32 NF1 patients. We report the identification of 45 independent somatic NF1 mutations, 20 of which are reported for the first time. Different types of point mutations together with LOH affecting the NF1 gene and its surrounding region or extending along the 17q arm have been found. Among point mutations, those affecting the correct splicing of the NF1 gene are common, coinciding with results reported on germline NF1 mutations. In most cases, we have been able to confirm that both copies of the NF1 gene are inactivated. We have also found that both somatic and germline mutations can be expressed at the RNA level in the neoplastic cells. Furthermore, we have observed that the study of more than one tumor derived from the same patient is useful for the identification of the germline mutation. Finally, we have noticed that the culture of neurofibromas and their fibroblast clearance facilitates LOH detection in cases in which it is difficult to determine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409870     DOI: 10.1007/s004390100514

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  16 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

2.  A 38-year review of oral schwannomas and neurofibromas in a Brazilian population: clinical, histopathological and immunohistochemical study.

Authors:  George João Ferreira do Nascimento; Danielle de Albuquerque Pires Rocha; Hébel Cavalcanti Galvão; Antônio de Lisboa Lopes Costa; Lélia Batista de Souza
Journal:  Clin Oral Investig       Date:  2010-03-09       Impact factor: 3.573

3.  PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

Authors:  Vincent W Keng; Eric P Rahrmann; Adrienne L Watson; Barbara R Tschida; Christopher L Moertel; Walter J Jessen; Tilat A Rizvi; Margaret H Collins; Nancy Ratner; David A Largaespada
Journal:  Cancer Res       Date:  2012-06-14       Impact factor: 12.701

4.  Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation.

Authors:  Debra A Mayes; Tilat A Rizvi; Jose A Cancelas; Nathan T Kolasinski; Georgianne M Ciraolo; Anat O Stemmer-Rachamimov; Nancy Ratner
Journal:  Cancer Res       Date:  2011-05-06       Impact factor: 12.701

Review 5.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 6.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

7.  Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.

Authors:  Jon P Williams; Jianqiang Wu; Gunnar Johansson; Tilat A Rizvi; Shyra C Miller; Hartmut Geiger; Punam Malik; Wenling Li; Yoh-suke Mukouyama; Jose A Cancelas; Nancy Ratner
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

8.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

9.  The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Authors:  Meena Upadhyaya; Gill Spurlock; Lan Kluwe; Nadia Chuzhanova; Emma Bennett; Nick Thomas; Abhijit Guha; Victor Mautner
Journal:  Neurogenetics       Date:  2009-02-17       Impact factor: 2.660

10.  Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras.

Authors:  Frances Hannan; Ivan Ho; James Jiayuan Tong; Yinghua Zhu; Peter Nurnberg; Yi Zhong
Journal:  Hum Mol Genet       Date:  2006-03-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.